Adma Biologics (ADMA) Retained Earnings (2011 - 2026)
Adma Biologics' (ADMA) quarterly Retained Earnings came in at -$161.7 million in Q4 2025, up 47.61% YoY from -$109.5 million in Q4 2024, and down 124.29% on a QoQ basis from $665.4 million in Q3 2025.
Adma Biologics (ADMA) Retained Earnings (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Retained Earnings data on file, last reported at -$161.7 million in Q4 2025.
- Quarterly Retained Earnings rose 47.61% year-over-year to -$161.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$161.7 million (up 47.61% YoY) and the FY2025 annual result came in at -$161.7 million, up 47.61% from the prior year.
- Retained Earnings declined to -$161.7 million in Q4 2025, from $665.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $665.4 million in Q3 2025 to a low of -$506.3 million in Q4 2023.
- A 5-year average of $252.7 million and a median of $558.6 million in 2021 frame the typical range for Retained Earnings.
- The widest YoY moves for Retained Earnings: up 249.62% in 2022, down 193.49% in 2022.
- Tracing ADMA's Retained Earnings over 5 years: stood at $553.3 million in 2021, then sank by 186.4% to -$478.0 million in 2022, then retreated by 5.91% to -$506.3 million in 2023, then jumped by 39.05% to -$308.6 million in 2024, then soared by 47.61% to -$161.7 million in 2025.
- The last three Retained Earnings figures came in at -$161.7 million (Q4 2025), $665.4 million (Q3 2025), and $660.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 675.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 675.14 Mn |
| Dec 31, 2025 | -161.65 Mn |
| Sep 30, 2025 | 665.38 Mn |
| Jun 30, 2025 | 660.91 Mn |
| Mar 31, 2025 | 655.07 Mn |
| Dec 31, 2024 | -308.58 Mn |
| Sep 30, 2024 | 652.35 Mn |
| Jun 30, 2024 | 644.63 Mn |
| Mar 31, 2024 | 642.13 Mn |
| Dec 31, 2023 | -506.26 Mn |
| Sep 30, 2023 | -488.61 Mn |
| Jun 30, 2023 | 637.92 Mn |
| Mar 31, 2023 | 630.44 Mn |
| Dec 31, 2022 | -478.02 Mn |
| Sep 30, 2022 | -465.78 Mn |
| Jun 30, 2022 | 565.27 Mn |
| Mar 31, 2022 | 564.03 Mn |
| Dec 31, 2021 | 553.27 Mn |
| Sep 30, 2021 | 498.23 Mn |
| Jun 30, 2021 | -377.80 Mn |